Reducing Enlarged Heart Cuts Diabetes Risk
Posted on: Thursday, 1 November 2007, 18:00 CDT
Patients with high blood pressure, who are treated to prevent or reduce an enlarged heart may decrease their risk of diabetes, New York researchers found.
Physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York said high-blood-pressure patients treated for enlarged heart, or left ventricular hypertrophy, who have regression or prevention of left ventricular hypertrophy found a 38 percent reduced risk of developing diabetes for high-blood-pressure patients and a 26 percent reduced risk after adjusting for other risk factors for diabetes.
The study, published in Hypertension, used data from the Losartan Intervention for Endpoint Reduction in Hypertension study conducted between 1995 and 2001.
A healthy heart is a prerequisite for the health of the body as a whole. Our previous research has shown that treating enlarged heart in high-blood-pressure patients reduces the risk for a variety of cardiovascular conditions, Dr. Peter Okin, of Weill Cornell Medical College and attending physician at NewYork-Presbyterian/Weill Cornell, said in a statement.
This new study finds an important new benefit -- namely a better chance of avoiding diabetes among patients who exhibit a reduction of their hypertrophy during treatment.
Source: United Press International
Related Articles
- Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
- Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
- Previously Unrecognized Harm of Intensified Glucose Lowering Reported in High Risk Patients With Type 2 Diabetes
- MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who Are Overweight
- Lipitor Reduced the Risk of Coronary Events By Half and Stroke By Nearly One-Third in High-Risk Patients With Type 2 Diabetes Who Experienced a Recent Stroke
- New Data Show ACTOS(R) (Pioglitazone HCl) Halted Progression of Atherosclerosis As Indicated By CIMT in Patients With Type 2 Diabetes
- ACTOS(R) (Pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients With Type 2 Diabetes
- Isis Pharmaceuticals Reports Positive Phase 2 Data: ISIS 113715 Improves Glucose Control in Patients With Type 2 Diabetes
- Whole Grains Cut Diabetes, Heart Disease Risk-Study
- The Effect of Irbesartan in Reducing Cardiovascular Risk in Hypertensive Type 2 Diabetic Patients: an Observational Study in 16 600 Patients in Primary Care
 |
 |
User Comments (0)
RSS Feeds